TWI694986B - 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 - Google Patents
經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 Download PDFInfo
- Publication number
- TWI694986B TWI694986B TW104142848A TW104142848A TWI694986B TW I694986 B TWI694986 B TW I694986B TW 104142848 A TW104142848 A TW 104142848A TW 104142848 A TW104142848 A TW 104142848A TW I694986 B TWI694986 B TW I694986B
- Authority
- TW
- Taiwan
- Prior art keywords
- amino
- methylphenyl
- phenyl
- cyclopentyl
- acid
- Prior art date
Links
- 0 **c1c(*)c(*)c(*)c(*)c1* Chemical compound **c1c(*)c(*)c(*)c(*)c1* 0.000 description 2
- YTRYVMRCTNOCOL-UHFFFAOYSA-N CC(CC(O)=O)c1cccc(NC(C(C2CCC2)c2ccc(-c3cncc(C(F)(F)F)c3)c(F)c2)=O)c1C Chemical compound CC(CC(O)=O)c1cccc(NC(C(C2CCC2)c2ccc(-c3cncc(C(F)(F)F)c3)c(F)c2)=O)c1C YTRYVMRCTNOCOL-UHFFFAOYSA-N 0.000 description 2
- LIFFFSRDNOKQKZ-UHFFFAOYSA-N CC(C(O)=O)Oc1cccc(NC(C(C2CCCC2)c(cc2)ccc2-c2cnc(C)c(Cl)c2)=O)c1C Chemical compound CC(C(O)=O)Oc1cccc(NC(C(C2CCCC2)c(cc2)ccc2-c2cnc(C)c(Cl)c2)=O)c1C LIFFFSRDNOKQKZ-UHFFFAOYSA-N 0.000 description 1
- STCYPKHHZKEGMK-UHFFFAOYSA-N CC(C)Cc1cncc(-c2ccc(C(C3CCCC3)C(Nc3c(C)c(CCC(O)=O)ccc3)=O)cc2)c1 Chemical compound CC(C)Cc1cncc(-c2ccc(C(C3CCCC3)C(Nc3c(C)c(CCC(O)=O)ccc3)=O)cc2)c1 STCYPKHHZKEGMK-UHFFFAOYSA-N 0.000 description 1
- QTYZIHUQYLPTEJ-UHFFFAOYSA-N CC(CC(O)=O)c1cccc(NC(C(C2CCC2)c(cc2)ccc2-c2cc(C(F)(F)F)cnc2)=O)c1C Chemical compound CC(CC(O)=O)c1cccc(NC(C(C2CCC2)c(cc2)ccc2-c2cc(C(F)(F)F)cnc2)=O)c1C QTYZIHUQYLPTEJ-UHFFFAOYSA-N 0.000 description 1
- WUXMFDWIWUSRIQ-UHFFFAOYSA-N CC(CC(O)=O)c1cccc(NC(C(C2CCC2)c(cc2)ccc2-c2cnc(C)c(Cl)c2)=O)c1C Chemical compound CC(CC(O)=O)c1cccc(NC(C(C2CCC2)c(cc2)ccc2-c2cnc(C)c(Cl)c2)=O)c1C WUXMFDWIWUSRIQ-UHFFFAOYSA-N 0.000 description 1
- WVFCPUMLDXWLRI-UHFFFAOYSA-N CC(CC(O)=O)c1cccc(NC(C(C2CCCC2)c2ccc(-c3cc(Cl)c(C)nc3)c(F)c2)=O)c1C Chemical compound CC(CC(O)=O)c1cccc(NC(C(C2CCCC2)c2ccc(-c3cc(Cl)c(C)nc3)c(F)c2)=O)c1C WVFCPUMLDXWLRI-UHFFFAOYSA-N 0.000 description 1
- ZKESDPLLYKBBLM-UHFFFAOYSA-N CC(Cc1cccc(NC(C(C2CCCC2)c(cc2)ccc2-c2cc(Cl)cnc2)=O)c1C)C(O)=O Chemical compound CC(Cc1cccc(NC(C(C2CCCC2)c(cc2)ccc2-c2cc(Cl)cnc2)=O)c1C)C(O)=O ZKESDPLLYKBBLM-UHFFFAOYSA-N 0.000 description 1
- UMPBNYVHWUZKKI-UHFFFAOYSA-N CCC(CC(O)=O)c1cccc(NC(C(c(cc2)ccc2-c2cc(C(F)(F)F)c(C)nc2)=C2CCCC2)=O)c1C Chemical compound CCC(CC(O)=O)c1cccc(NC(C(c(cc2)ccc2-c2cc(C(F)(F)F)c(C)nc2)=C2CCCC2)=O)c1C UMPBNYVHWUZKKI-UHFFFAOYSA-N 0.000 description 1
- LYKIORHCTTZOAL-WUKNDPDISA-N CCOC(/C(/C)=C/c1cccc(NC(C(C2CCCC2)c(cc2)ccc2Br)=O)c1C)=O Chemical compound CCOC(/C(/C)=C/c1cccc(NC(C(C2CCCC2)c(cc2)ccc2Br)=O)c1C)=O LYKIORHCTTZOAL-WUKNDPDISA-N 0.000 description 1
- YYLKPOUGGOCMAO-UHFFFAOYSA-N CCOc1cc(-c2ccc(C(C3CCC3)C(Nc3c(C)c(CCC(O)=O)ccc3)=O)cc2)cnc1 Chemical compound CCOc1cc(-c2ccc(C(C3CCC3)C(Nc3c(C)c(CCC(O)=O)ccc3)=O)cc2)cnc1 YYLKPOUGGOCMAO-UHFFFAOYSA-N 0.000 description 1
- DKJNRQYOATUQSD-UHFFFAOYSA-N CCOc1cncc(-c2ccc(C(C3CCCC3)C(Nc3c(C)c(CCC(O)=O)cc(F)c3)=O)cc2)c1 Chemical compound CCOc1cncc(-c2ccc(C(C3CCCC3)C(Nc3c(C)c(CCC(O)=O)cc(F)c3)=O)cc2)c1 DKJNRQYOATUQSD-UHFFFAOYSA-N 0.000 description 1
- UBERMLGPLAMOAV-UHFFFAOYSA-N Cc(c(Br)c1)cc(C(C2CCCC2)C(Nc2c(C)c(CCC(OC)=O)ccc2)=O)c1F Chemical compound Cc(c(Br)c1)cc(C(C2CCCC2)C(Nc2c(C)c(CCC(OC)=O)ccc2)=O)c1F UBERMLGPLAMOAV-UHFFFAOYSA-N 0.000 description 1
- XFLFZYXYNFKETI-UHFFFAOYSA-N Cc(c(C(C1)C1C(OC)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1Br)=O Chemical compound Cc(c(C(C1)C1C(OC)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1Br)=O XFLFZYXYNFKETI-UHFFFAOYSA-N 0.000 description 1
- FRVHHWCNMORGDK-UHFFFAOYSA-N Cc(c(CCC(O)=O)cc(F)c1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cnc(C)c(Cl)c1)=O Chemical compound Cc(c(CCC(O)=O)cc(F)c1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cnc(C)c(Cl)c1)=O FRVHHWCNMORGDK-UHFFFAOYSA-N 0.000 description 1
- SNJVXEVRMWGISW-UHFFFAOYSA-N Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCC1)c(cc1)cc(F)c1-c1cc(C(F)(F)F)c(C)nc1)=O Chemical compound Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCC1)c(cc1)cc(F)c1-c1cc(C(F)(F)F)c(C)nc1)=O SNJVXEVRMWGISW-UHFFFAOYSA-N 0.000 description 1
- VNSSZYUUZGLDIH-UHFFFAOYSA-N Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCC1)c(cc1)ccc1-c1cncc(C(F)(F)F)c1)=O Chemical compound Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCC1)c(cc1)ccc1-c1cncc(C(F)(F)F)c1)=O VNSSZYUUZGLDIH-UHFFFAOYSA-N 0.000 description 1
- LUWOXMQWGOWQSN-UHFFFAOYSA-N Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cncc(Cl)c1)=O Chemical compound Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cncc(Cl)c1)=O LUWOXMQWGOWQSN-UHFFFAOYSA-N 0.000 description 1
- ZHJUHIJQNZYCGP-UHFFFAOYSA-N Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cncc(OC(F)F)c1)=O Chemical compound Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cncc(OC(F)F)c1)=O ZHJUHIJQNZYCGP-UHFFFAOYSA-N 0.000 description 1
- OYQZHTOHAMOKKQ-UHFFFAOYSA-N Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cncc(OC)c1)=O Chemical compound Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cncc(OC)c1)=O OYQZHTOHAMOKKQ-UHFFFAOYSA-N 0.000 description 1
- YJQZWOJTRNXAMW-UHFFFAOYSA-N Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(ccc(-c1cncc(C(F)(F)F)c1)c1)c1Cl)=O Chemical compound Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(ccc(-c1cncc(C(F)(F)F)c1)c1)c1Cl)=O YJQZWOJTRNXAMW-UHFFFAOYSA-N 0.000 description 1
- SWMJVNJTIZRMTI-UHFFFAOYSA-N Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCCC1)c(cc1)ccc1-c1cc(C(F)(F)F)cnc1)=O Chemical compound Cc(c(CCC(O)=O)ccc1)c1NC(C(C1CCCCC1)c(cc1)ccc1-c1cc(C(F)(F)F)cnc1)=O SWMJVNJTIZRMTI-UHFFFAOYSA-N 0.000 description 1
- OJBXKOLKYVKMAP-UHFFFAOYSA-N Cc(c(NCC(OC)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1Br)=O Chemical compound Cc(c(NCC(OC)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1Br)=O OJBXKOLKYVKMAP-UHFFFAOYSA-N 0.000 description 1
- GMALHSWNLMGJLT-UHFFFAOYSA-N Cc(c(OCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cc(Cl)cnc1)=O Chemical compound Cc(c(OCC(O)=O)ccc1)c1NC(C(C1CCCC1)c(cc1)ccc1-c1cc(Cl)cnc1)=O GMALHSWNLMGJLT-UHFFFAOYSA-N 0.000 description 1
- ZZZPPOMRAFGYIR-UHFFFAOYSA-N OC(C(C1CCCC1)c(ccc(-c1cncc(C(F)(F)F)c1)c1)c1Cl)=O Chemical compound OC(C(C1CCCC1)c(ccc(-c1cncc(C(F)(F)F)c1)c1)c1Cl)=O ZZZPPOMRAFGYIR-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14199006.9 | 2014-12-18 | ||
EP14199006 | 2014-12-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201625549A TW201625549A (zh) | 2016-07-16 |
TWI694986B true TWI694986B (zh) | 2020-06-01 |
Family
ID=52133974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104142848A TWI694986B (zh) | 2014-12-18 | 2015-12-18 | 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 |
Country Status (30)
Country | Link |
---|---|
US (1) | US10172814B2 (es) |
EP (1) | EP3233802A1 (es) |
JP (1) | JP2017537957A (es) |
KR (1) | KR20170098869A (es) |
CN (1) | CN107257790A (es) |
AR (1) | AR103156A1 (es) |
AU (1) | AU2015367540B2 (es) |
BR (1) | BR112017012844A2 (es) |
CA (1) | CA2970987A1 (es) |
CL (1) | CL2017001588A1 (es) |
CO (1) | CO2017005983A2 (es) |
CR (1) | CR20170258A (es) |
CU (1) | CU24413B1 (es) |
DO (1) | DOP2017000142A (es) |
EA (1) | EA035788B1 (es) |
EC (1) | ECSP17038136A (es) |
GT (1) | GT201700126A (es) |
IL (1) | IL252683B (es) |
MA (1) | MA41171A (es) |
MX (1) | MX2017008091A (es) |
MY (1) | MY182134A (es) |
NI (1) | NI201700077A (es) |
PE (1) | PE20171247A1 (es) |
PH (1) | PH12017501122A1 (es) |
SG (1) | SG11201704971UA (es) |
SV (1) | SV2017005465A (es) |
TN (1) | TN2017000256A1 (es) |
TW (1) | TWI694986B (es) |
UY (1) | UY36461A (es) |
WO (1) | WO2016097013A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
WO2018067762A2 (en) * | 2016-10-05 | 2018-04-12 | The Global Alliance For Tb Drug Development, Inc. | Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections |
CN110590548B (zh) * | 2019-09-06 | 2020-09-08 | 中国药科大学 | Akr1c3抑制剂或其可药用的盐、其制备方法及用途 |
CN118748993A (zh) | 2021-12-28 | 2024-10-08 | 日本新药株式会社 | 吲唑化合物和药物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102083803A (zh) * | 2008-04-14 | 2011-06-01 | 拜耳先灵制药股份公司 | 氧代杂环取代的羧酸衍生物和它的用途 |
TW201127373A (en) * | 2009-10-28 | 2011-08-16 | Bayer Schering Pharma Ag | Substituted 3-phenylpropionic acids and the use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0200997A3 (en) | 1999-04-28 | 2003-03-28 | Sanofi Aventis Deutschland | Tri-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them |
EP1375472A4 (en) | 2001-03-30 | 2008-12-10 | Eisai R&D Man Co Ltd | BENZENE COMPOUND AND SALT THEREOF |
WO2004099170A2 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
CN1875002B (zh) | 2003-11-05 | 2011-08-03 | 霍夫曼-拉罗奇有限公司 | 作为ppar激动剂的苯基衍生物 |
EA011010B1 (ru) | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
MX2013006053A (es) | 2010-12-07 | 2013-06-18 | Bayer Ip Gmbh | Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso. |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
-
2015
- 2015-12-16 WO PCT/EP2015/080041 patent/WO2016097013A1/en active Application Filing
- 2015-12-16 US US15/537,280 patent/US10172814B2/en not_active Expired - Fee Related
- 2015-12-16 KR KR1020177019444A patent/KR20170098869A/ko unknown
- 2015-12-16 PE PE2017001094A patent/PE20171247A1/es unknown
- 2015-12-16 MX MX2017008091A patent/MX2017008091A/es unknown
- 2015-12-16 SG SG11201704971UA patent/SG11201704971UA/en unknown
- 2015-12-16 TN TN2017000256A patent/TN2017000256A1/en unknown
- 2015-12-16 MA MA041171A patent/MA41171A/fr unknown
- 2015-12-16 CN CN201580076218.8A patent/CN107257790A/zh active Pending
- 2015-12-16 BR BR112017012844A patent/BR112017012844A2/pt not_active Application Discontinuation
- 2015-12-16 EP EP15810650.0A patent/EP3233802A1/en not_active Withdrawn
- 2015-12-16 CA CA2970987A patent/CA2970987A1/en not_active Abandoned
- 2015-12-16 CU CU2017000083A patent/CU24413B1/es unknown
- 2015-12-16 MY MYPI2017702201A patent/MY182134A/en unknown
- 2015-12-16 AU AU2015367540A patent/AU2015367540B2/en not_active Ceased
- 2015-12-16 JP JP2017532082A patent/JP2017537957A/ja not_active Ceased
- 2015-12-16 EA EA201791365A patent/EA035788B1/ru not_active IP Right Cessation
- 2015-12-16 CR CR20170258A patent/CR20170258A/es unknown
- 2015-12-18 UY UY0001036461A patent/UY36461A/es not_active Application Discontinuation
- 2015-12-18 AR ARP150104175A patent/AR103156A1/es unknown
- 2015-12-18 TW TW104142848A patent/TWI694986B/zh not_active IP Right Cessation
-
2017
- 2017-06-05 IL IL252683A patent/IL252683B/en not_active IP Right Cessation
- 2017-06-15 PH PH12017501122A patent/PH12017501122A1/en unknown
- 2017-06-16 CO CONC2017/0005983A patent/CO2017005983A2/es unknown
- 2017-06-16 NI NI201700077A patent/NI201700077A/es unknown
- 2017-06-16 SV SV2017005465A patent/SV2017005465A/es unknown
- 2017-06-16 CL CL2017001588A patent/CL2017001588A1/es unknown
- 2017-06-16 GT GT201700126A patent/GT201700126A/es unknown
- 2017-06-16 DO DO2017000142A patent/DOP2017000142A/es unknown
- 2017-06-19 EC ECIEPI201738136A patent/ECSP17038136A/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102083803A (zh) * | 2008-04-14 | 2011-06-01 | 拜耳先灵制药股份公司 | 氧代杂环取代的羧酸衍生物和它的用途 |
TW201127373A (en) * | 2009-10-28 | 2011-08-16 | Bayer Schering Pharma Ag | Substituted 3-phenylpropionic acids and the use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI694986B (zh) | 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 | |
JP5826961B2 (ja) | 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類 | |
JP6907351B2 (ja) | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 | |
JP2021535169A (ja) | Teadモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体 | |
TWI666202B (zh) | 作為mIDH1抑制劑之苯并咪唑-2-胺 | |
JP5913400B2 (ja) | 核内受容体結合剤 | |
JP6824952B2 (ja) | mIDH1阻害剤としての2−アリール−および2−アリールアルキル−ベンズイミダゾール | |
JP2016519674A (ja) | 過剰増殖障害を治療または予防するための3−アセチルアミノ−1−(フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ)ベンゼン誘導体 | |
CN103582632B (zh) | 取代的苯并咪唑 | |
JP6787899B2 (ja) | 医薬的活性化合物 | |
JP2017505793A (ja) | mIDH1阻害剤としてのベンズイミダゾール−2−アミン | |
JP7161474B2 (ja) | ブラジキニンb1受容体の拮抗薬としてのカルボン酸芳香族アミド類 | |
JPWO2015190489A1 (ja) | 新規抗癌剤 | |
WO2018114783A1 (en) | Tetrazole containing compounds | |
TW202241398A (zh) | 含有ep2拮抗劑之醫藥組成物 | |
KR20110001378A (ko) | 전립선암 치료 효과를 갖는 비칼루타미드의 인산 에스테르 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |